Redefine your XLH treatment with CRYSVITA® (burosumab-twza)

Clinical studies of adults with XLH have shown that CRYSVITA can help by:

CRYSVITA led to increased and maintained serum phosphorus levels within the normal range

Increasing and maintaining phosphorus levels in the blood

CRYSVITA led to the healing of fractures and osteomalacia

Healing fractures and osteomalacia

The risks and benefits of treatment with CRYSVITA were studied in a total of 148 adults with XLH

Study 3

  • Number of patients: 134
  • Ages: 19-66 years old
  • Length of treatment: 24 weeks

Study 4

  • Number of patients: 14
  • Ages: 25-52 years old
  • Length of treatment: 48 weeks
CRYSVITA helped increase and maintain phosphorus levels in the normal range
CRYSVITA helped increase and maintain phosphorus levels in the normal range

Serum phosphorus

Phosphorus is a mineral that is important for healthy bones. Adults with XLH have too little phosphorus, leading to weakening of their bones. In Study 3, adults with XLH were given either CRYSVITA or a placebo (an injection that did not contain any active medicine) every 4 weeks for 24 weeks, and the amount of phosphorus in their blood, described as “serum phosphorus,” was measured.

CRYSVITA helped increase and maintain serum phosphorus levels within the normal range*

In a study of adults with XLH aged 19 to 66 years (Study 3), 68 adults received CRYSVITA and 66 adults received placebo every 4 weeks.

94% of patients achieved serum phosphorus levels in the normal range compared to 8% in placebo
94% of patients achieved serum phosphorus levels in the normal range compared to 8% in placebo
  • *Normal levels of serum phosphorus for this group of patients ranged from 2.5 to 4.5 milligrams/deciliter (mg/dL). The normal range of serum phosphorus varies by age and gender.

At baseline, both patients in the CRYSVITA and placebo groups had phosphorus levels below the normal range. After 24 weeks of treatment with CRYSVITA or placebo every 4 weeks, there were more patients who achieved phosphorus levels within the normal range in the CRYSVITA group than in the placebo group.

Remember the treatment goals?

Talk to your doctor about how CRYSVITA can help increase and maintain normal serum phosphorus levels.

CRYSVITA led to the healing of fractures
CRYSVITA led to the healing of fractures

Fractures

In adults with XLH, ongoing osteomalacia can result in what’s called “low trauma” fractures or pseudofractures. Pseudofracture is a kind of fracture where the bone thickens at the site of an injury but is not completely broken. These symptoms can manifest as a result of bearing weight on weak bones.

CRYSVITA helped heal fractures

In a study of adults with XLH aged 19 to 66 years (Study 3), 68 adults received CRYSVITA and 66 adults received placebo every 4 weeks. At the beginning of the study, there were 65 total fractures in the CRYSVITA group and 91 total fractures in the placebo group.

CRYSVITA led to a higher rate of fracture healing compared to placebo
CRYSVITA led to a higher rate of fracture healing compared to placebo

During treatment through Week 24, a total of 6 new fractures or pseudofractures appeared in 68 patients in the CRYSVITA group, compared to 8 new abnormalities in 66 patients in the placebo group.

Remember the treatment goals?

Talk to your doctor about how CRYSVITA can help with fracture healing.

CRYSVITA led to the healing of osteomalacia
CRYSVITA led to the healing of osteomalacia

Osteomalacia

Under normal conditions, minerals like phosphorus are continuously added to bones. This process, called “mineralization,” helps to keep bones hard. People with XLH don’t have enough phosphorus for bones to properly mineralize, which causes some parts of the bone to become “soft” and more likely to break. “Softening” and weakening of the bones is called osteomalacia.

In a study of adults with XLH aged 25 to 52 years (Study 4), small samples of bone were taken and examined for signs of healing of osteomalacia. Bone samples were taken before patients started treatment with CRYSVITA and then again after the patients were treated with CRYSVITA every 4 weeks for 48 weeks.

CRYSVITA helped heal osteomalacia

In Study 4, 14 adults with XLH aged 25 to 52 years received CRYSVITA every 4 weeks.

CRYSVITA led to the healing of osteomalacia
CRYSVITA led to the healing of osteomalacia

Healing of osteomalacia was observed in 10 out of 14 (71%) patients. Their bone biopsies showed a 57% reduction in osteoid volume to bone volume, which is a measurement of mineralized bone.

Remember the treatment goals?

Talk to your doctor about how CRYSVITA can help heal osteomalacia.